Drugs / 89Zr-GSK2849330
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02345174 | Mar 2015 → Jun 2016 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-GSK2849330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02345174 ↗ |
| Route | Intravenous | “89Zr-GSK2849330 solution for intravenous administration” NCT02345174 ↗ |